Skip to content

Prospective clinical research on the impact of peripheral myopic defocus glasses on the onset of myopia

Prospective clinical research on the impact of peripheral myopic defocus glasses on the onset of myopia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093329
Enrollment
Unknown
Registered
2024-12-03
Start date
2024-12-07
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

control group:Non-prescription defocus lenses
Clinical study group 1:Microlens +3.50D peripheral defocus lens
Clinical study group 2:Annular defocus +3.50D peripheral defocus lens
Clinical study group 3:Annular defocus +1.50D peripheral defocus lens

Sponsors

Air Force Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 6 and 15 years old; 2. Equivalent spherical refractive error: -0.25 to +0.75 D; 3. Astigmatism and anisometropia below 1.50 D; 4. Uncorrected visual acuity of each eye is not less than 0.8, and the best-corrected visual acuity of each eye is not less than 1.0. 5. Voluntarily participate in this project and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Strabismus and binocular vision abnormalities; 2.Previous use of medications or lenses to control myopia. 3.Allergy to cycloplegia; 4.Eye diseases: macular diseases, moderate to severe dry eye, corneal diseases, cataracts, vitreoretinal diseases, infectious conjunctivitis, uveitis, optic nerve damage, congenital optic nerve developmental abnormalities, or other ocular diseases; 5. Autoimmune diseases (including lupus erythematosus, dermatomyositis, Sjögren's syndrome, etc.); 6. Systemic diseases (such as hypertension, lupus erythematosus, albinism, etc.); 7. Children and adolescents with other diseases (such as a history of seizures, tic disorders, incomplete central nervous system development, epilepsy, mental and psychological disorders, etc.).

Design outcomes

Primary

MeasureTime frame
Axial;Refraction;

Secondary

MeasureTime frame
Accommodation and convergence function;

Countries

China

Contacts

Public ContactLinsong Qi

Air Force Medical Center

qilinsong06@qq.com+86 133 1138 1237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026